Form 8-K

8-K — BIOLIFE SOLUTIONS INC

Accession: 0001628280-26-054288

Filed: 2026-08-06

Period: 2026-08-06

CIK: 0000834365

SIC: 3845 (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — blfs-20260806.htm (Primary)

EX-99.1 (q22026earningsrelease.htm)

GRAPHIC (address-blockx3.jpg)

GRAPHIC (blfs_symbol.jpg)

GRAPHIC (logo.jpg)

GRAPHIC (preserve-thexpromise.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: blfs-20260806.htm · Sequence: 1

blfs-20260806

false0000834365Nasdaq00008343652026-08-062026-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2026

BioLife Solutions, Inc.

(Exact name of registrant as specified in its charter)

Delaware 001-36362 94-3076866

(State or other jurisdiction of

incorporation) (Commission File Number) (IRS Employer Identification No.)

3303 Monte Villa Parkway,

Bothell, WA 98021

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (425) 402-1400

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading symbol Name of exchange on which registered

Common Stock, par value $0.001 per share BLFS

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On August 6, 2026, BioLife Solutions, Inc. (the “Company”) issued a press release announcing unaudited financial results and operational highlights for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.

The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1

Press release, dated August 6, 2026

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioLife Solutions, Inc.

Date: August 6, 2026

By: /s/ Troy Wichterman

Name: Troy Wichterman

Title: Chief Financial Officer

EX-99.1

Filename: q22026earningsrelease.htm · Sequence: 2

Document

BioLife Solutions Reports Second Quarter 2026 Financial Results

Total revenue of $28.5 million, up 21% over Q2 2025

GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65%

GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income tax benefit, and non-GAAP adjusted EBITDA of $7.4 million, or 26% of revenue

Repligen to acquire BioLife and the proposed transaction is expected to close in the fourth quarter of 2026

BOTHELL, Wash. (August 6, 2026) – BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (“CGT”) market, announces financial results for the three and six months ended June 30, 2026.

“We delivered another strong quarter, with solid execution across the business led by our market-leading biopreservation media franchise,” said Roderick de Greef, Chairman and Chief Executive Officer of BioLife. “This continued performance underscores the important role our technologies play in enabling the advancement of cell and gene therapies. We look forward to building on this foundation through our announced combination with Repligen, which is expected to close in the fourth quarter of 2026.”

Second Quarter 2026 Business Highlights

•On July 21, 2026, BioLife entered into a definitive agreement under which Repligen, subject to customary closing conditions, will acquire BioLife for a total enterprise value of approximately $1.5 billion, comprised of $11.25 cash and 0.1442 shares of Repligen’s common stock, on a per share basis of BioLife’s common stock. As a result of the merger, BioLife will cease to be a publicly traded company. The transaction is expected to close in the fourth quarter of 2026, subject to approval by BioLife stockholders, regulatory approvals and other customary closing conditions.

•Our biopreservation media is utilized in approximately 250 ongoing commercially sponsored clinical trials in the U.S., representing a more than 70% market share. This includes over 30 Phase III trials, or nearly 80% of these late-stage trials. Our CellSeal vials and hPL products are used in over 35 clinical trials.

•Our biopreservation media is embedded in 18 unique commercial CGTs as of June 30, 2026, with expectations that approvals for 8 additional products, geographic expansions, earlier lines of treatment, or new indications will occur over the next 12 months. Our CellSeal cryogenic vials and hPL products are embedded in four approved therapies.

Second Quarter 2026 Financial Results

BioLife is presenting various financial metrics under U.S. generally accepted accounting principles (GAAP) and as adjusted (non-GAAP). In addition, BioLife completed the divestiture of evo in 2025, and is presenting its financial condition and operating results as discontinued operations for all periods presented within the Unaudited Condensed Consolidated Balance

Page 1

Sheets and Unaudited Condensed Consolidated Statements of Operations. The Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) and Unaudited Condensed Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and disclosures for all periods presented reflect only the continuing operations of the Company unless otherwise noted.

REVENUE

•Total revenue for the second quarter of 2026 was $28.5 million, an increase of $5.0 million, or 21%, from $23.4 million for the second quarter of 2025 and up $1.0 million, or 4%, from the first quarter of 2026.

•Total revenue for the six months ended June 30, 2026 was $56.0 million, an increase of $10.5 million, or 23%, from $45.5 million for the six months ended June 30, 2025.

GROSS MARGIN

•Gross margin (GAAP) for the second quarter of 2026 was 64% compared with 65% for the second quarter of 2025. Adjusted gross margin (non-GAAP) for the second quarter of 2026 was 65% compared with 66% for the second quarter of 2025.

•Gross margin (GAAP) for the six months ended June 30, 2026 was 64% compared with 66% for the six months ended June 30, 2025. Adjusted gross margin (non-GAAP) for the six months ended June 30, 2026 was 65% compared with 67% for the six months ended June 30, 2025.

OPERATING INCOME / (LOSS)

•Operating income (GAAP) for the second quarter of 2026 was $1.7 million compared with an operating loss of $16.1 million for the second quarter of 2025. Adjusted operating income (non-GAAP) for the second quarter of 2026 was $3.1 million compared with an adjusted operating loss of $0.3 million for the second quarter of 2025.

•Operating income (GAAP) for the six months ended June 30, 2026 was $1.7 million compared with an operating loss of $16.6 million for the six months ended June 30, 2025. Adjusted operating income (non-GAAP) for the six months ended June 30, 2026 was $4.1 million compared with $0.9 million for the six months ended June 30, 2025.

NET INCOME / (LOSS)

•Net income (GAAP) for the second quarter of 2026 was $45.1 million compared with a net loss of $15.3 million for the second quarter of 2025. Adjusted net income (non-GAAP) for the second quarter of 2026 was $4.2 million compared with $0.6 million for the second quarter of 2025. Due to the release of our valuation allowance during the second quarter of 2026, we recognized a non-cash income tax benefit of $42.4 million.

Page 2

•Net income (GAAP) for the six months ended June 30, 2026 was $46.3 million compared with a net loss of $15.1 million for the six months ended June 30, 2025. Adjusted net income (non-GAAP) for the six months ended June 30, 2026 was $6.3 million compared with $2.6 million for the six months ended June 30, 2025.

NET INCOME / (LOSS) PER SHARE

•Net income per share (GAAP) for the second quarter of 2026 was $0.92 compared with net loss per share of $0.32 for the second quarter of 2025. The release of our valuation allowance during the second quarter of 2026 had an $0.87 impact on our net income per share.

•Net income per share (GAAP) for the six months ended June 30, 2026 was $0.95 compared with net loss per share of $0.31 for the six months ended June 30, 2025. The release of our valuation allowance during the six months ended June 30, 2026 had an $0.87 impact on our income per share.

ADJUSTED EBITDA

•Adjusted EBITDA, a non-GAAP measure, for the second quarter of 2026 was $7.4 million, or 26% of revenue, compared with $5.6 million, or 24% of revenue, for the second quarter of 2025.

•Adjusted EBITDA, a non-GAAP measure, for the six months ended June 30, 2026 was $13.5 million, or 24% of revenue, compared with $11.0 million, or 24% of revenue, for the six months ended June 30, 2025.

CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES

•Cash, cash equivalents, and marketable securities as of June 30, 2026 were $113.1 million.

(As a result of presenting amounts in millions, rounding differences may exist in the percentages above.)

Conference Call & Webcast

Due to the pending acquisition of BioLife by Repligen, BioLife will not be hosting a conference call.

About BioLife Solutions

BioLife is a leading developer and supplier of cell processing tools and services for the CGT market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development,

Page 3

manufacturing and distribution. For more information, please visit www.biolifesolutions.com, and follow BioLife on LinkedIn and X.

Cautions Regarding Forward Looking Statements

Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “plans,” “expects,” “believes,” “anticipates,” “designed,” “may,” “estimate,” “guidance,” and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

Non-GAAP Measures of Financial Performance

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included on a consolidated basis in this release: adjusted gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release.

We believe these non-GAAP financial measures are useful to investors in assessing our operating performance. We use these financial measures internally to evaluate our operating performance and for planning and forecasting of future periods. We also believe it is in the best interests of investors to provide this non-GAAP information.

While we believe these non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of these non-GAAP financial measures. These non-GAAP financial measures may not be reported by competitors, and they may not be directly comparable to similarly titled measures of other companies due to differences in calculation methodologies. The non-GAAP financial measures are not an alternative to GAAP information and are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures. They should be used only as a supplement to GAAP information and should be considered only in conjunction with our consolidated financial statements prepared in accordance with GAAP.

Page 4

Media & Investor Relations

At the Company

Troy Wichterman

Chief Financial Officer

(425) 402-1400

twichterman@biolifesolutions.com

John Graziano

Investor Relations

jgraziano@biolifesolutions.com

Investors

Alliance Advisors IR

Vivian Cervantes

(973) 873-7724

vcervantes@allianceadvisors.com

Page 5

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, amounts in thousands, except share and per share amounts)

Three Months Ended June 30, Six Months Ended June 30,

(In thousands, except per share and share data) 2026 2025 2026 2025

Revenue $ 28,466 $ 23,438 $ 55,966 $ 45,492

Cost of revenue 10,179 8,203 20,182 15,457

Gross profit 18,287 15,235 35,784 30,035

Operating expenses:

General and administrative 10,694 11,232 22,901 22,582

Sales and marketing 2,782 2,577 5,308 5,020

Research and development 2,958 1,965 5,608 3,404

IPR&D expense — 15,521 — 15,521

Intangible asset amortization 157 66 242 132

Total operating expenses 16,591 31,361 34,059 46,659

Operating income (loss) 1,696 (16,126) 1,725 (16,624)

Other income:

Interest income, net 994 684 2,035 1,365

Other income 63 247 242 349

Total other income, net 1,057 931 2,277 1,714

Income (loss) before income tax (benefit) expense 2,753 (15,195) 4,002 (14,910)

Income tax (benefit) expense (42,351) 126 (42,288) 140

Net income (loss) from continuing operations $ 45,104 $ (15,321) $ 46,290 $ (15,050)

Discontinued operations:

Loss from discontinued operations before income tax expense — (517) — (1,236)

Income tax benefit — — — —

Loss from discontinued operations $ — $ (517) $ — $ (1,236)

Net income (loss) $ 45,104 $ (15,838) $ 46,290 $ (16,286)

Earnings (loss) per share - Basic:

Continuing operations $ 0.92 $ (0.32) $ 0.95 $ (0.31)

Discontinued operations $ — $ (0.01) $ — $ (0.03)

Net income (loss) $ 0.92 $ (0.33) $ 0.95 $ (0.34)

Earnings (loss) per share - Diluted:

Continuing operations $ 0.91 $ (0.32) $ 0.94 $ (0.31)

Discontinued operations $ — $ (0.01) $ — $ (0.03)

Net income (loss) $ 0.91 $ (0.33) $ 0.94 $ (0.34)

Weighted average shares used to compute net loss per share attributable to common shareholders:

Basic 48,866,822 47,798,146 48,663,807 47,468,266

Diluted 49,294,679 47,798,146 49,259,528 47,468,266

Page 6

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited, amounts in thousands)

Three Months Ended

June 30, Six Months Ended

June 30,

(In thousands) 2026 2025 2026 2025

Net income (loss) $ 45,104 $ (15,838) $ 46,290 $ (16,286)

Other comprehensive (loss) income (91) 38 (343) 47

Comprehensive income (loss) $ 45,013 $ (15,800) $ 45,947 $ (16,239)

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION

(Unaudited, amounts in thousands)

June 30, December 31,

(In thousands) 2026 2025

Cash, cash equivalents, and marketable securities $ 113,070 $ 120,177

Working capital 121,251 113,582

Current assets 135,198 136,561

Total assets 447,494 405,884

Current liabilities 13,947 22,979

Long-term obligations 13,544 11,017

Accumulated deficit (293,406) (339,696)

Total shareholders' equity $ 420,003 $ 371,888

Page 7

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS INFORMATION

(Unaudited, amounts in thousands)

Six Months Ended

June 30,

(In thousands) 2026 2025

Net cash provided by operating activities $ 5,857 $ 9,095

Net cash used in investing activities (3,409) (66,709)

Net cash used in financing activities (11,489) (5,870)

Net decrease in cash and cash equivalents $ (9,041) $ (63,484)

Cash and cash equivalents – beginning of period $ 33,038 $ 95,386

Cash and cash equivalents – end of period 23,997 31,902

Marketable securities 89,073 68,335

Total cash, cash equivalents, and marketable securities $ 113,070 $ 100,237

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP ADJUSTED GROSS MARGIN

(Unaudited, amounts in thousands)

Three Months Ended

June 30, Six Months Ended

June 30,

(In thousands) 2026 2025 2026 2025

Revenue $ 28,466 $ 23,438 $ 55,966 $ 45,492

Cost of revenue (10,179) (8,203) (20,182) (15,457)

GROSS PROFIT $ 18,287 $ 15,235 $ 35,784 $ 30,035

GROSS MARGIN 64 % 65 % 64 % 66 %

ADJUSTMENTS TO GROSS PROFIT:

Gain on disposal of assets — — (6) (12)

Intangible asset amortization 241 266 481 525

ADJUSTED GROSS PROFIT $ 18,528 $ 15,501 $ 36,259 $ 30,548

ADJUSTED GROSS MARGIN 65 % 66 % 65 % 67 %

Page 8

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP OPERATING EXPENSES TO NON-GAAP ADJUSTED OPERATING EXPENSES

(Unaudited, amounts in thousands)

Three Months Ended

June 30, Six Months Ended

June 30,

(In thousands) 2026 2025 2026 2025

OPERATING EXPENSES $ 16,591 $ 31,361 $ 34,059 $ 46,659

ADJUSTMENTS TO OPERATING EXPENSES

Acquisition and divestiture costs (787) 59 (1,016) (941)

Severance costs (206) — (612) (416)

IPR&D expense — (15,521) — (15,521)

Intangible asset amortization (157) (66) (242) (132)

Loss on disposal of assets — — 9 10

ADJUSTED OPERATING EXPENSES $ 15,441 $ 15,833 $ 32,198 $ 29,659

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP OPERATING INCOME / (LOSS) TO NON-GAAP ADJUSTED OPERATING INCOME / (LOSS)

(Unaudited, amounts in thousands)

Three Months Ended

June 30, Six Months Ended

June 30,

(In thousands) 2026 2025 2026 2025

OPERATING INCOME / (LOSS) $ 1,696 $ (16,126) $ 1,725 $ (16,624)

ADJUSTMENTS TO OPERATING INCOME / (LOSS)

Acquisition and divestiture costs 787 (59) 1,016 941

Severance costs 206 — 612 416

IPR&D expense — 15,521 — 15,521

Intangible asset amortization 398 332 723 657

Gain on disposal of assets — — (9) (10)

ADJUSTED OPERATING INCOME / (LOSS) $ 3,087 $ (332) $ 4,067 $ 901

Page 9

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME / (LOSS) FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED NET INCOME

(Unaudited, amounts in thousands)

Three Months Ended

June 30, Six Months Ended

June 30,

(In thousands) 2026 2025 2026 2025

NET INCOME / (LOSS) FROM CONTINUING OPERATIONS $ 45,104 $ (15,321) $ 46,290 $ (15,050)

ADJUSTMENTS TO NET INCOME / (LOSS) FROM CONTINUING OPERATIONS

Acquisition and divestiture costs 787 (59) 1,016 941

Severance costs 206 — 612 416

IPR&D expense — 15,521 — 15,521

Intangible asset amortization 398 332 723 657

Gain on disposal of assets — — (9) (10)

Income tax (benefit) expense (42,351) 126 (42,288) 140

Other expense (income) 12 (47) (45) (44)

ADJUSTED NET INCOME $ 4,156 $ 552 $ 6,299 $ 2,571

Page 10

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME / (LOSS) FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED EBITDA

(Unaudited, amounts in thousands)

Three Months Ended

June 30, Six Months Ended

June 30,

(In thousands) 2026 2025 2026 2025

NET INCOME / (LOSS) FROM CONTINUING OPERATIONS $ 45,104 $ (15,321) $ 46,290 $ (15,050)

ADJUSTMENTS:

Interest income, net (994) (684) (2,035) (1,365)

Accretion of available-for-sale investments (75) (200) (197) (305)

Income tax (benefit) expense (42,351) 126 (42,288) 140

Depreciation 411 200 785 384

Intangible asset amortization 398 332 723 657

EBITDA $ 2,493 $ (15,547) $ 3,278 $ (15,539)

OTHER ADJUSTMENTS:

Share-based compensation (non-cash) 3,854 5,707 8,660 9,689

Acquisition and divestiture costs 787 (59) 1,016 941

Severance costs 206 — 612 416

IPR&D expense — 15,521 — 15,521

Gain on disposal of assets — — (9) (10)

Other expense (income) 12 (47) (45) (44)

ADJUSTED EBITDA $ 7,352 $ 5,575 $ 13,512 $ 10,974

% of Revenue 26 % 24 % 24 % 24 %

Page 11

GRAPHIC

Filename: address-blockx3.jpg · Sequence: 6

Binary file (54124 bytes)

Download address-blockx3.jpg

GRAPHIC

Filename: blfs_symbol.jpg · Sequence: 7

Binary file (19612 bytes)

Download blfs_symbol.jpg

GRAPHIC

Filename: logo.jpg · Sequence: 8

Binary file (42308 bytes)

Download logo.jpg

GRAPHIC

Filename: preserve-thexpromise.jpg · Sequence: 9

Binary file (30637 bytes)

Download preserve-thexpromise.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 11

v3.26.1

Cover

Aug. 06, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Aug. 06, 2026

Entity Registrant Name

BioLife Solutions, Inc

Entity Incorporation, State or Country Code

Entity File Number

001-36362

Entity Tax Identification Number

94-3076866

Entity Address, Address Line One

3303 Monte Villa Parkway

Entity Address, City or Town

Bothell

Entity Address, State or Province

Entity Address, Postal Zip Code

98021

City Area Code

425

Local Phone Number

402-1400

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

BLFS

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Amendment Flag

false

Entity Central Index Key

0000834365

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration